Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Exogenous GLP-1 slows gastric emptying in health and diabetes leading to diminished glycemic excursions.

Gastric emptying is markedly accelerated by hypoglycemia.

The primary objective was to determine whether GLP-1 attenuates the acceleration of gastric emptying induced by hypoglycemia.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

Gastric emptying was measured scintigraphically from T = 0 to 180 min and serum 3-OMG taken at 15-min intervals.

The areas under the curve for gastric emptying and 3-OMG concentration were analyzed using one-way repeated-measures ANOVA with Bonferroni-Holm adjusted post hoc tests.

What Was Measured

The subject headings attached to it are Blood Glucose, Gastric Emptying, Glucagon-Like Peptide 1, Glucose Clamp Technique, Healthy Volunteers, Hypoglycemia and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page, all human trials.